Session information

Morning Seminar

MS2-2 Targeted therapy for AML: a focus upon recently-approved agents.

Sat. Oct 12, 2019 7:55 AM - 8:40 AM No.2 (Tokyo International Forum, 7F Hall B7(1))

Chair: Hideaki Nakajima（Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine）

Sponsor: DAIICHI SANKYO COMPANY, LIMITED

[MS2-2] Targeted therapy for AML: a focus upon recently-approved agents.

Alexander E. Perl (Associate Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania; Leukemia Program, Abramson Cancer Center at the University of Pennsylvania)

▲